|
|
Post by harryx1 on Sept 8, 2015 7:58:00 GMT -5
|
|
|
|
Post by od on Sept 8, 2015 8:10:15 GMT -5
"Significant A1C Reduction" - Powerful claim. |
|
|
|
Post by babaoriley on Sept 8, 2015 9:43:23 GMT -5
Very unusual and very creative ad. Harry, I certainly understand your comment, as the woman would seem to be very lonely in a world like that! But they got the message out and by the time they were listing the side effects/warnings, I found myself "studying" the art behind it all, and therefore almost did not notice it at all.
|
|
|
|
Post by peppy on Sept 8, 2015 10:10:24 GMT -5
"Significant A1C Reduction" - Powerful claim. 14.1 Overview of Clinical Studies
The safety and effectiveness of TOUJEO given once-daily was compared to that of once-daily LANTUS in open-label, randomized, active-control, parallel studies of up to 26 weeks in patients with type 1 diabetes mellitus and patients with type 2 diabetes mellitus (Tables 3 and 4). At trial end, the reduction in glycated hemoglobin (HbA1c) and fasting plasma glucose with TOUJEO titrated to goal was similar to that with LANTUS titrated to goal. At the end of the trial, depending on the patient population and concomitant therapy, patients were receiving a higher dose of TOUJEO than LANTUS.
14.2 Clinical Study in Adult Patients with Type 1 Diabetes
In an open-label, controlled study (Study A), patients with type 1 diabetes (n=546), were randomized to basal-bolus treatment with TOUJEO or LANTUS and treated for 26 weeks. TOUJEO and LANTUS were administered once daily in the morning (time period covering from pre-breakfast until pre-lunch) or in the evening (time period defined as prior to the evening meal until at bedtime). A mealtime insulin analogue was administered before each meal. Mean age was 47.3 years and mean duration of diabetes was 21 years. 57% were male. 85.1% were Caucasian, 4.7% Black or African American. 4.7% were Hispanic. 32.2 percent of patients had GFR>90 mL/min/1.73m2. The mean BMI was approximately 27.6%. At week 26, treatment with TOUJEO provided a mean reduction in HbA1c that met the pre-specified non-inferiority margin of 0.4% (Table 3). Patients treated with TOUJEO used 17.5% more basal insulin than patients treated with LANTUS. There were no clinically important differences in glycemic control when TOUJEO was administered once daily in the morning or in the evening. There were no clinically important differences in body weight between treatment groups. www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538lbl.pdf
|
|
|
|
Post by dreamboatcruise on Sept 8, 2015 11:04:01 GMT -5
Very unusual and very creative ad. Harry, I certainly understand your comment, as the woman would seem to be very lonely in a world like that! But they got the message out and by the time they were listing the side effects/warnings, I found myself "studying" the art behind it all, and therefore almost did not notice it at all. You're probably onto something there. Would imagine distraction from the required commentary is part of the formula. Imagine if they were required to illustrate all that commentary with suitable images... we'd never use any drugs. |
|
|
|
Post by notamnkdmillionaire on Sept 8, 2015 11:07:51 GMT -5
All I thought is, "typical that they'd have a black woman in a white world! How racist!"  |
|
|
|
Post by avogadro on Sept 8, 2015 11:23:40 GMT -5
But they got the message out and by the time they were listing the side effects/warnings, I found myself "studying" the art behind it all, and therefore almost did not notice it at all. Yes, but key words like "Life Threatening" , "Heart Failure" and "Death" got me back on message rather quickly. Will they top those in the legendary Afrezza TV ad, which of course is "just around the corner, like all things Afrezza. |
|
|
|
Post by mssciguy on Sept 8, 2015 11:33:33 GMT -5
Correct me if I am wrong, but pwd don't want constant insulin levels, right? Need those mealtime spikes, hence the value of Afrezza. So why say, "don't mix with other insulins"?
Seems like mixed messages from Sanofi, or is that standard FDA talk?
|
|
|
|
Post by nylefty on Sept 8, 2015 11:35:15 GMT -5
As somebody pointed out on StockTwits, "Toujeo has 33% Tier 2 vs. 4% for Afrezza. Ads right now would be a waste." Those insurance coverage percentages are from www.formularylookup.com |
|
|
|
Post by harryx1 on Sept 8, 2015 11:35:44 GMT -5
But they got the message out and by the time they were listing the side effects/warnings, I found myself "studying" the art behind it all, and therefore almost did not notice it at all. Yes, but key words like "Life Threatening" , "Heart Failure" and "Death" got me back on message rather quickly. Will they top those in the legendary Afrezza TV ad, which of course is "just around the corner, like all things Afrezza. Please tell me what ad followed the Toujeo ad in Time Magazine. Also, have you listened to any other drug commercial before? |
|
|
|
Post by orlon on Sept 8, 2015 13:11:51 GMT -5
But they got the message out and by the time they were listing the side effects/warnings, I found myself "studying" the art behind it all, and therefore almost did not notice it at all. Yes, but key words like "Life Threatening" , "Heart Failure" and "Death" got me back on message rather quickly. Will they top those in the legendary Afrezza TV ad, which of course is "just around the corner, like all things Afrezza. Also key words at the end of the commercial that says something to the effect, 'do not mix or use other insulin or solutions with Toujeo.' Does this exclude AFREZZA? |
|
|
|
Post by tayl5 on Sept 8, 2015 13:41:42 GMT -5
In the clinical trial cited above, Toujeo was used with a prandial bolus insulin. The warning must mean, don't combine Toujeo with a long-acting basal Novo Nordisk product.
|
|
